Skip to main content
Premium Trial:

Request an Annual Quote

Linden Bioscience Licenses mRNA Amplification Technology from Incyte

NEW YORK, July 7 - Linden Bioscience said today that it has licensed mRNA amplification technology from Incyte to be used in an RNA amplification and archival kit based upon Linden Bioscience's solid phase transcription chain reaction (SP-TCR) technology.


Linden entered a non-exclusive license agreement for linear mRNA amplification technology protected by three US patents (5,716,785; 5,891,636; and 6,291,170) assigned to the Board of Trustees of Leland Stanford Junior University and exclusively licensed to Incyte. Linear amplification technology is based upon antisense RNA amplification, which, according to Linden, is able to maintain the relative ratios of the starting mRNA population better than exponential amplification methods such as nucleic acid sequence-based amplification or RT-PCR.


The combination of Linden's and Incyte's RNA technologies will "produce quantities of RNA sufficient for gene expression profiling experiments without the need for large amounts of initial mRNA sample," according to Linden. The combined technology will also allow researchers to store and later amplify the mRNA of interest without introducing bias in the amplified product, the company said.


Linden said the new amplification product would be available "in the next few months."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.